MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.05% | 46.29% | 35.83% | 35.29% | 23.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.21% | 179.87% | 164.38% | 94.55% | 36.15% |
| Operating Income | -156.21% | -179.87% | -164.38% | -94.55% | -36.15% |
| Income Before Tax | -208.07% | -222.81% | -175.01% | -56.75% | -4.09% |
| Income Tax Expenses | 71.56% | 138.23% | 199.26% | 367.87% | 444.61% |
| Earnings from Continuing Operations | -207.55% | -222.52% | -175.06% | -57.11% | -4.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.86% | -49.18% | -71.39% | -71.81% | -63.51% |
| Net Income | -221.44% | -256.99% | -230.31% | -76.82% | -18.21% |
| EBIT | -156.21% | -179.87% | -164.38% | -94.55% | -36.15% |
| EBITDA | -156.46% | -179.69% | -162.47% | -92.69% | -34.39% |
| EPS Basic | -208.47% | -206.97% | -147.85% | -19.67% | 23.13% |
| Normalized Basic EPS | -218.89% | -231.54% | -185.79% | -28.90% | 16.13% |
| EPS Diluted | -208.47% | -206.97% | -147.85% | -19.67% | 23.13% |
| Normalized Diluted EPS | -218.89% | -231.54% | -185.79% | -28.90% | 16.13% |
| Average Basic Shares Outstanding | 5.67% | 14.69% | 28.17% | 41.78% | 50.71% |
| Average Diluted Shares Outstanding | 5.67% | 14.69% | 28.17% | 41.78% | 50.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |